|
|
Article: Allergan reports strong 4th-qtr results.(Allergan America)(Brief Article)
- Article from:
- Pharma Marketletter
- Article date:
- February 13, 2006
CopyrightCOPYRIGHT 2006 Marketletter Publications Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
California, USA-based Allergan says that its net sales in the quarter ended December 31, 2005, were $594.9 million, an increase of 11.3% on the year-earlier comparable period. The firm's earnings per share for the period also increased to $0.90 from $0.85 achieved during the fourth-quarter of 2004.
The company says that a key factor in its prosperity in 2005 was the long-term agreement which it signed with UK drug major GlaxoSmithKilne to develop and promote Allergan's Botox (botulinum toxin type-a) in Japan and China. The deal also covers the co-promotion of GSK's Imitrex STATdose system (sumatriptan) and Amerge (naratriptan hydrochloride), in the USA.
...